Recent 8-K filings for KIDS
Highest-materiality recent filing
OrthoPediatrics Q1 revenue $52.4M (+17% YoY); raises FY2025 guidance to $236-242M
- Total Q1 revenue $52.4M (+17% YoY); U.S. revenue $40.9M (+19%), international $11.5M (+11%).
- Net loss $10.7M ($0.46 per share) vs. $7.8M ($0.34) in Q1 2024; adjusted EBITDA loss improved to ($0.4M) from ($1.1M).
-
OrthoPediatrics Q1 revenue up 13% to $59.4M; lifts FY2026 guidance to $263-267M
Revenue $59.4M (13% YoY); US +11%, International +22%; Trauma & Deformity +14%, Scoliosis +13%.
-
Company will use the attached investor presentation in upcoming analyst and investor meetings.
-
OrthoPediatrics adds $20M delayed draw term loan facility via credit agreement amendment
Amendment creates $20M delayed draw term loan facility; draws allowed until June 30, 2027 in minimum $10M increments.
-
Record FY2025 revenue $236.3M, up 15% from $204.7M in 2024.
-
OrthoPediatrics files Feb 2026 investor presentation with no material new disclosures
Filing furnishes an investor presentation dated February 2026 for upcoming analyst meetings.
-
OrthoPediatrics posts record FY2025 revenue $236.1M (+15% YoY); guides FY2026 revenue $262-266M
Q4 2025 revenue $61.3M (+16% YoY); domestic $48.4M (+13%), international $12.9M (+32%).
-
OrthoPediatrics files investor presentation for upcoming meetings; no material new disclosures
Filing discloses upcoming investor presentations using Exhibit 99.1, a 2026 investor presentation.
-
Revenue $61.2M, +12% YoY (17% ex-7D capital); Trauma & Deformity +17%, Scoliosis +4%.
-
OrthoPediatrics files investor presentation for October 2025; no specific financial data disclosed
Filing under Item 7.01 for upcoming investor meetings; presentation slides furnished as Exhibit 99.1.
-
OrthoPediatrics preliminary Q3 rev $61.2M (+12% YoY); cuts FY guidance to $233.5-$234.5M
Preliminary Q3 net revenue $61.2M, up 12% YoY; domestic $48.7M (+14%), international $12.5M (+6%).
-
OrthoPediatrics board member Schlotterback retires; Kelly Fischer appointed
Terry Schlotterback resigned from Board effective Aug. 8, 2025, due to retirement; no disagreement.
-
OrthoPediatrics expands specialty bracing into California, Ohio, Colorado, New York, and Ireland
First OPSB clinic in California opens in Los Angeles market, providing access to millions of potential patients.
-
OrthoPediatrics Q2 revenue hits record $61.1M (+16% YoY); raises FY2025 guidance
Revenue of $61.1M (+16% YoY); domestic up 17%, international up 12%.
-
OrthoPediatrics files August 2025 investor presentation; no specific metrics disclosed
Investor presentation filed as Exhibit 99.1 with no financial results or operational updates in the filing text.
-
Elected four directors: Fred L. Hite (17.1M for), Bryan W. Hughes (18.0M for), Samuel D. Riccitelli (11.5M for), Mark C. Throdahl (16.3M for); note significant withheld votes for Riccitelli (7.7M).
-
OrthoPediatrics amends Medtech Concepts acquisition; remaining $3.75M due in stock instead of cash
First Amendment replaces three $1.25M cash earn-outs with unregistered common stock installments.
-
OrthoPediatrics Q1 revenue $52.4M (+17% YoY); raises FY2025 guidance to $236-242M
Total Q1 revenue $52.4M (+17% YoY); U.S. revenue $40.9M (+19%), international $11.5M (+11%).
-
OrthoPediatrics files May 2025 investor presentation; no material new details
Presentation furnished as Exhibit 99.1 for upcoming analyst and investor meetings.
-
OrthoPediatrics files investor presentation with no new material information
Filing announces upcoming investor presentations using Exhibit 99.1.
-
Full year 2024 revenue $204.7M, up 38% from $148.7M in 2023; Q4 revenue $52.7M, up 40% YoY.
-
OrthoPediatrics files investor presentation for upcoming meetings, no financial details disclosed
Company filed a Regulation FD disclosure (Item 7.01) regarding upcoming investor and analyst presentations.
-
OrthoPediatrics reports record FY2024 revenue of $204.7M (+38% YoY), issues 2025 guidance
Preliminary unaudited FY2024 revenue $204.7M, up 38% from $148.7M in 2023.
-
Executive officers will use the presentation in upcoming meetings with analysts and investors.
-
OrthoPediatrics Q3 record revenue $54.6M (+37% YoY); raises FY guidance to $202-204M
Revenue $54.6M (+37% YoY); domestic up 45%, international up 12%.
-
OrthoPediatrics inks new employment pacts with CEO, CFO, and three other NEOs
CEO Bailey base salary $550k; CFO Hite $501k; Odle/Gerritzen $368k; Hauser $400k.
-
OrthoPediatrics holds Investor Day on Sept 12, 2024; notes >1M kids helped
Investor Day presentation on September 12, 2024 with investor and analyst meetings.
-
OrthoPediatrics closes $25M term loan and $50M convertible notes issuance
$25M term loan from Braidwell LP funded on August 12, 2024.
-
OrthoPediatrics provides investor presentation for August 2024; details not disclosed in filing.
Company furnished an investor presentation dated August 2024 for use in meetings with investors and analysts.
-
Term loan at SOFR + 6.50% (PIK option adds 1.00%), interest-only until August 2029 maturity.
-
OrthoPediatrics reports record Q2 revenue up 33% to $52.8M; net loss widens to $6.0M
Q2 2024 revenue $52.8M (+33% YoY); U.S. +39%, Intl +16%. Trauma & Deformity +37%, Scoliosis +26%.
-
OrthoPediatrics stockholders approve 2024 Incentive Award Plan, replacing 2017 plan
Board adopted the 2024 Incentive Award Plan on Feb 29, 2024, with stockholder approval obtained on May 24, 2024.
-
OrthoPediatrics stockholders elect directors, approve compensation and incentive plan
David R. Bailey, Marie C. Infante, Jimmy D. McDonald elected as directors with 91.1%, 63.8%, 71.4% of votes cast respectively.
-
Company furnished an investor presentation (Exhibit 99.1) for upcoming analyst and investor meetings.
-
OrthoPediatrics Q1 revenue up 41% to $44.7M; raises FY 2024 guidance to $200-203M
Total revenue $44.7M (+41% YoY); U.S. +44%, international +33%.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.42 · Most common event earnings